Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 15Other hematologic neoplasm 14Lymphoid 5Plasma cell 4Thoracic 2Dermatologic 2Classical hematology 2Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 244Lung Neoplasms 77Melanoma 57Carcinoma, Renal Cell 44Small Cell Lung Carcinoma 33Colorectal Neoplasms 28Squamous Cell Carcinoma of Head and Neck 24Carcinoma, Transitional Cell 24Neoplasms 23Triple Negative Breast Neoplasms 22Neoplasm Metastasis 21Carcinoma, Hepatocellular 19Ovarian Neoplasms 17Mesothelioma 17Pancreatic Neoplasms 15Mesothelioma, Malignant 15Stomach Neoplasms 13Breast Neoplasms 13Uterine Cervical Neoplasms 12Urinary Bladder Neoplasms 10Head and Neck Neoplasms 10Carcinoma, Merkel Cell 10Kidney Neoplasms 9Adenocarcinoma of Lung 8Esophageal Neoplasms 7Endometrial Neoplasms 7Lymphoma 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Prostatic Neoplasms 5

Interventions

Azacitidine 4Nivolumab 2sargramostim 1ruxolitinib 1rucaparib 1incomplete Freund's adjuvant 1cc-486 1bemcentinib 1abiraterone 1Tretinoin 1TTI-621 1Standard of Care 1Rituximab 1Radiotherapy 1Practice Guidelines as Topic 1Polymerase Chain Reaction 1Palliative Care 1Paclitaxel 1Methylprednisolone 1Melphalan 1Injections 1Immunoenzyme Techniques 1INCB059872 1INCB057643 1Gemcitabine 1Flow Cytometry 1Cyclosporine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Nivolumab × Thoracic × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Pfizer

Phase 1 Terminated
249 enrolled 43 charts
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡